InicioPodcastsThe Long Run with Luke TimmermanEp209: Mathai Mammen on Developing Drugs Against Undruggable TargetsThe Long Run with Luke TimmermanEp209: Mathai Mammen on Developing Drugs Against Undruggable Targets9 de septiembre de 2026 · 1 h 36 minReproducir episodioCompartir desde este puntoNotas del episodioMathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.Todos los episodios de The Long Run with Luke Timmerman